Paragon Biosciences LLC β Full Portfolio
6 tracked investments Β· listed companies and verified rows first
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
BoardAaron Royston(Director)in
Co-investorsAisling CapitalValor Equity PartnersvenBio PartnersVivo Capital
CiRC Biosciences develops cellular reprogramming therapies that convert fibroblasts directly into specific neurons and cell types lost in degenerative eye and brain diseases.
BiotechDeep TechMedical Devices
Co-investorsPortal Innovations
Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a lead investigational asset, ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome.
BiotechDigital Health
Co-investorsValor Equity Partners
Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome.
BiotechMedical Devices
Co-investorsBain Capital Life SciencesFidelity InvestmentsValor Equity Partners
Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases.
AI & Machine LearningBiotechDeep TechHealthtechChicago, US
Aris Theologis(Executive Officer, Director)inDarien Parhad(Executive Officer)Patrick J. Morris(Executive Officer, Director)Marc Yoskowitz(CEO)inRama Ranganathan(Executive Officer, Director)
BoardJeffrey S. Aronin(Director)
Co-investorsOrbiMedFidelity InvestmentsNVenturesNVIDIAValor Equity Partners
Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
BiotechDeep TechMedical DevicesExton, US
Matthew Gantz(President and Chief Executive Officer)inDavid ChuinMichael TownsleyChristopher J. LarsoninRhea WilliamsinJude Sullivan(Executive Officer)
Co-investorsValor Equity PartnersFidelity InvestmentsHorizon
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.